A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate

Sunitinib is a tyrosine kinase inhibitor approved for the treatment of multiple solid tumors. However, cardiotoxicity is of increasing concern, with a need to develop rational mechanism driven approaches for the early detection of cardiac dysfunction. We sought to interrogate changes in cardiac ener...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 12; no. 1; p. e0169964
Main Authors O'Farrell, Alice C, Evans, Rhys, Silvola, Johanna M U, Miller, Ian S, Conroy, Emer, Hector, Suzanne, Cary, Maurice, Murray, David W, Jarzabek, Monika A, Maratha, Ashwini, Alamanou, Marina, Udupi, Girish Mallya, Shiels, Liam, Pallaud, Celine, Saraste, Antti, Liljenbäck, Heidi, Jauhiainen, Matti, Oikonen, Vesa, Ducret, Axel, Cutler, Paul, McAuliffe, Fionnuala M, Rousseau, Jacques A, Lecomte, Roger, Gascon, Suzanne, Arany, Zoltan, Ky, Bonnie, Force, Thomas, Knuuti, Juhani, Gallagher, William M, Roivainen, Anne, Byrne, Annette T
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 01.01.2017
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Sunitinib is a tyrosine kinase inhibitor approved for the treatment of multiple solid tumors. However, cardiotoxicity is of increasing concern, with a need to develop rational mechanism driven approaches for the early detection of cardiac dysfunction. We sought to interrogate changes in cardiac energy substrate usage during sunitinib treatment, hypothesising that these changes could represent a strategy for the early detection of cardiotoxicity. Balb/CJ mice or Sprague-Dawley rats were treated orally for 4 weeks with 40 or 20 mg/kg/day sunitinib. Cardiac positron emission tomography (PET) was implemented to investigate alterations in myocardial glucose and oxidative metabolism. Following treatment, blood pressure increased, and left ventricular ejection fraction decreased. Cardiac [18F]-fluorodeoxyglucose (FDG)-PET revealed increased glucose uptake after 48 hours. [11C]Acetate-PET showed decreased myocardial perfusion following treatment. Electron microscopy revealed significant lipid accumulation in the myocardium. Proteomic analyses indicated that oxidative metabolism, fatty acid β-oxidation and mitochondrial dysfunction were among the top myocardial signalling pathways perturbed. Sunitinib treatment results in an increased reliance on glycolysis, increased myocardial lipid deposition and perturbed mitochondrial function, indicative of a fundamental energy crisis resulting in compromised myocardial energy metabolism and function. Our findings suggest that a cardiac PET strategy may represent a rational approach to non-invasively monitor metabolic pathway remodeling following sunitinib treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: There are no competing interests associated with the publication of this manuscript and the commercial affiliations do not alter our adherence to PLOS ONE policies on sharing data and materials.
Conceptualization: ATB.Data curation: SH AD PC.Formal analysis: ACOF RE ISM DWM MAJ AM GMU MJ VO AD PC.Funding acquisition: ATB.Investigation: ACOF RE JMUS ISM EC SH MC DWM MAJ AM MA GMU LS AS HL MJ VO SG.Methodology: ATB RE ACOF JAR RL JK AR.Project administration: ATB.Resources: FMM WMG.Supervision: CP.Visualization: ACOF ATB.Writing – original draft: ACOF ISM DWM MAJ JMUS EC ATB.Writing – review & editing: ACOF ZA BK TF ATB.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0169964